Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine

▴ Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities and subject to contract, to the COVAX Facility.

Sanofi and GSK have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19 vaccines.

Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities and subject to contract, to the COVAX Facility. Both Companies intend to contribute to COVAX’s ambition to ensure successful COVID-19 vaccines reach those in need, whoever they are and wherever they live, once they obtain appropriate approvals.

“To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. “This moment also reflects our long-term commitment to global health and ensures our COVID-19 vaccines are affordable and accessible to those most at risk, everywhere in the world.”

Roger Connor, President of GSK Vaccines added, “"Since we started working on the development of COVID-19 vaccines, GSK has pledged to make them available to people around the world. We are proud to be working with Sanofi to make this adjuvanted recombinant protein-based vaccine available to the countries signed up to the COVAX Facility as soon as possible - this has the potential to be a significant contribution to the global fight against COVID-19.”

The COVAX Facility is part of COVAX, a global collaboration of governments, global health organizations, businesses and philanthropic organizations working to accelerate development, production, and equitable access to COVID-19 vaccines. COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO and forms the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. More than 180 countries and economies recently signed onto the COVAX Facility to get timely and cost-effective access to vaccines to meet the global scale of the COVID-19 pandemic.

Through the COVAX Facility’s efforts, vaccines will be distributed in participating countries through the WHO’s recently published Allocation Framework, and the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) Values Framework which has begun to frame future guidance on vaccine use. These allocation principles aim to ensure that people in all parts of the world will get access to COVID-19 vaccines once they are available.

Status of the adjuvanted recombinant protein-based vaccine development

Sanofi and GSK initiated a Phase 1/2 study on September 3 with a total of 440 subjects enrolled, and anticipate first results in early December 2020, to support the initiation of a pivotal Phase 3 study before the end of the year. If these data are sufficient for licensure application, it is planned to request regulatory approval from the first half of 2021. In parallel, the Companies are scaling up manufacturing of the antigen and adjuvant respectively.

On the front lines in the fight against COVID-19

In addition to the recombinant protein-based vaccine in collaboration with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio. With several innovative vaccine platforms currently being investigated across the industry, mRNA is considered among the most promising. Preclinical data showed that two immunizations of the mRNA vaccine induced high neutralizing antibody levels that are comparable to the upper range of those observed in infected humans. Sanofi expects the Phase 1/2 study to start in the fourth quarter of 2020, with earliest potential approval in the second half of 2021. Translate Bio has established mRNA manufacturing capacity and Sanofi expects to be able to supply annual capacity of 90 to 360 million doses.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally.

Tags : #Sanofi #gsk #covax #covid19vaccine #globalhealthcarecompanies

About the Author


Rohit Sharma

Writer, Health Enthusiast, and an Accountant, Rohit Sharma is a writer at medicircle, penning down his thoughts about healthcare research, innovations, trends in healthcare and simply all about healthcare. Write to rohit on [email protected]

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Uttarakhand govt makes Covid-19 test mandatory for entry November 30, 2020
Unichem gets US FDA approval for Atenolol and Chlorthalidone TabletsNovember 30, 2020
Dr Reddy’s buys select anti-allergy brands from Glenmark in Russia and other CIS countries November 30, 2020
Government Launches Mission COVID Suraksha to accelerate Indian COVID-19 Vaccine Development November 30, 2020
71% of the daily fatalities contributed by eight States/UT - Delhi, Maharashtra, WB, Haryana, Punjab, Kerala, Uttar Pradesh and RajasthanNovember 30, 2020
Rajasthan govt decides to close schools, colleges, cinema, entertainment parks in state till Dec 31 November 30, 2020
India Covid-19 News Updates :Nov 29, 2020November 29, 2020
PM congratulates scientists on progress of Covid19 vaccine at Bharat BiotechNovember 28, 2020
COVID-19 recovery rate in country stands at 93.68 percent.November 28, 2020
Vertex Pharma received European Commission Approval for SYMKEVI With KALYDECONovember 28, 2020
Co-Diagnostics JV CoSara Diagnostics receives clearance from CDSCO for COVID-19 2-Gene Multiplex TestNovember 28, 2020
SAL unveils new pharma and perishable facilities in Riyadh in time for COVID vaccines distributionNovember 28, 2020
Number of Covid tests per million population in country cross one lakh markNovember 28, 2020
How can I lower cholesterol with diet?November 28, 2020
Breakthrough in AML Treatment: GoldenBiotech reports new drug trial of Antroquinonol November 28, 2020
Gujarat records 1607 new cases of COVID-19November 28, 2020
Number of active cases of COVID-19 drop down to 120 in Andaman & Nicobar IslandsNovember 28, 2020
Number of covid-19 recoveries reach 3,09,747 in OdishaNovember 28, 2020
Frequent & rapid testing can eliminate Covid-19 spread within weeks: StudyNovember 28, 2020
Karnataka reports 1,526 new cases of Covid-19November 28, 2020